Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11986254 | 0.95 | MAPT (0.46) | MAPTHSD17B10TSHRALDH1A1CYP3A4 | |
| SCHEMBL17921016 | 0.92 | MAPT (0.58) | MAPTHSD17B10TSHRALDH1A1CYP3A4 | |
| SCHEMBL9964655 | 0.91 | MAPT (0.44) | MAPTHSD17B10TSHRALDH1A1CYP3A4 | |
| SCHEMBL17921032 | 0.90 | MAPT (0.61) | MAPTTSHRALDH1A1NAAAEPHX1 | |
| SCHEMBL15315316 | 0.89 | MAPT (0.54) | MAPTTSHRNAAA | |
| SCHEMBL28519812 | 0.88 | MAPT (0.48) | MAPTHSD17B10TSHRALDH1A1CYP3A4 | |
| SCHEMBL1007670 | 0.88 | MAPT (0.48) | MAPTHSD17B10TSHRALDH1A1CYP3A4 | |
| SCHEMBL15315329 | 0.87 | MAPT (0.57) | MAPTALDH1A1NAAA | |
| SCHEMBL9964651 | 0.85 | MAPT (0.39) | MAPTHSD17B10TSHRTDP1 | |
| SCHEMBL28188062 | 0.84 | HSD17B10 (0.52) | MAPTHSD17B10TSHRALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264728-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2016-09-15 | — | — | US | disclosed |
| US-9376531-B2 | Polycarbonate polyol compositions and methods | NOVOMER, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150299386-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2015-10-22 | — | — | US | disclosed |
| US-8921508-B2 | Polycarbonate polyol compositions and methods | NOVOMER, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140046008-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | NOVOMER, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140024795-A1 | ALIPHATIC POLYCARBONATE POLYOLS CONTAINING SILYL GROUPS | NOVOMER, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20130244864-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | NOVOMER, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8470956-B2 | Polycarbonate polyol compositions and methods | NOVOMER, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130066044-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | NOVOMER, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8247520-B2 | Polycarbonate polyol compositions and methods | NOVOMER, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110230580-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | Novomer, Inc (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230580-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | PARG, PUF60, PICALM | MAPT 3045/4885HSD17B10 2920/4885TSHR 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.